Loading clinical trials...
Loading clinical trials...
Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
Conditions
Interventions
MM-111
Paclitaxel
+1 more
Locations
21
United States
Birmingham, Alabama, United States
Los Angeles, California, United States
Los Angeles, California, United States
Stanford, California, United States
Denver, Colorado, United States
Ocala, Florida, United States
Start Date
January 1, 2013
Primary Completion Date
July 1, 2015
Completion Date
December 1, 2015
Last Updated
June 22, 2017
NCT07070466
NCT07358806
NCT06662110
NCT06510543
NCT02735057
NCT06189898
Lead Sponsor
Merrimack Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions